CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B Cell Mediated Autoimmune Disease

Sponsor
The Children's Hospital of Zhejiang University School of Medicine
Study ID
NCT07305116
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • ANCA Associated Systemic Vasculitis
  • Autoimmune Diseases
  • IgA Nephropathy (IgAN)
  • Multi-Drug Resistant Nephrotic Syndrome
  • Systemic Lupus Erthematosus (SLE)
  • Systemic Sclerosis (SSc)

Eligibility Criteria

Sex
ALL
Age
3 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • UCAR T-cell — BIOLOGICAL
    Universal allogeneic anti-CD19/BCMA CAR T-cells.

Study Details

CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B cell mediated autoimmune disease.

Key Dates

First listed
Dec 26, 2025
Start date
Dec 1, 2025
Status verified
Jan 2026
Primary completion
Dec 31, 2028
Completion
Dec 31, 2029

Study Design

Enrollment
15 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: UCAR T-cell group
    Universal allogeneic anti-CD19/BCMA CAR T-cells

Primary Outcome Measure

The number and severity of dose-limiting toxicity (DLT) events [ Time Frame: Within 28 Days After UCAR T-cell Infusion ]

Central Contacts

Related Studies